Literature DB >> 11273081

Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies.

S MacMahon1, R Collins.   

Abstract

Observational studies and randomised trials can contribute complementary evidence about the effects of treatment on mortality and on major non-fatal outcomes. In particular, observational studies have an important role in the identification of large adverse effects of treatment on infrequent outcomes (ie, rare, but serious, side-effects) that are not likely to be related to the indications for (or contraindications to) the treatment of interest. Such studies can also provide useful information about the risks of death and disability in particular circumstances that can help to generalise from clinical trials to clinical practice. But, due to their inherent potential for moderate or large biases, observational studies have little role in the direct assessment of any moderate effects of treatment on major outcomes that might exist. Instead, sufficiently large-scale evidence from randomised trials is needed to assess such treatment effects appropriately reliably. Wider appreciation of the different strengths and weaknesses of these two types of epidemiological study should increase the likelihood that the most reliable evidence available informs decisions about the treatments doctors use--and patients receive--for the management of a wide range of life-threatening conditions.

Entities:  

Mesh:

Year:  2001        PMID: 11273081     DOI: 10.1016/S0140-6736(00)04017-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

Review 1.  Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

Authors:  N Chapman; B Neal
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

2.  Evaluating treatment effects reliably.

Authors:  Martin J Landray; Gary Whitlock
Journal:  BMJ       Date:  2002-12-14

3.  Liberal or restrictive transfusion in high-risk patients after hip surgery.

Authors:  Jeffrey L Carson; Michael L Terrin; Helaine Noveck; David W Sanders; Bernard R Chaitman; George G Rhoads; George Nemo; Karen Dragert; Lauren Beaupre; Kevin Hildebrand; William Macaulay; Courtland Lewis; Donald Richard Cook; Gwendolyn Dobbin; Khwaja J Zakriya; Fred S Apple; Rebecca A Horney; Jay Magaziner
Journal:  N Engl J Med       Date:  2011-12-14       Impact factor: 91.245

4.  Clinical trials report. Good news and bad news: now the bad news.

Authors:  Norman M Kaplan
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

5.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

6.  Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

Review 7.  Antifibrinolytic therapy: evidence, bias, confounding (and politics!).

Authors:  Paul Myles
Journal:  J Extra Corpor Technol       Date:  2007-12

8.  Low birthweight and subsequent emotional and behavioural outcomes in 12-year-old children in Soweto, South Africa: findings from Birth to Twenty.

Authors:  Farnaz Sabet; Linda M Richter; Paul G Ramchandani; Alan Stein; Maria A Quigley; Shane A Norris
Journal:  Int J Epidemiol       Date:  2009-05-11       Impact factor: 7.196

Review 9.  An update on the salt wars-genuine controversy, poor science, or vested interest?

Authors:  Bruce Neal; Mary-Anne Land; Mark Woodward
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 10.  Study design issues in evaluating immune biomarkers.

Authors:  Ronald J Bosch; Xinyan Zhang; Netanya G Sandler
Journal:  Curr Opin HIV AIDS       Date:  2013-03       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.